BACKGROUND: The cost-utility of brief therapy compared with cognitive-behavioural therapy (CBT) and care as usual in the treatment of depression and anxiety has not yet been determined. AIMS: To assess the cost-utility of brief therapy compared with CBT and care as usual. METHOD: A pragmatic randomised controlled trial involving 702 patients was conducted at 7 Dutch mental healthcare centres (MHCs). Patients were interviewed at baseline and then every 3 months over a period of 1.5 years, during which time data were collected on direct costs, indirect costs and quality of life. RESULTS: The mean direct costs of treatment at the MHCs were significantly lower for brief therapy than for CBT and care as usual. However, after factoring in other healthcare costs and indirect costs, no significant differences between the treatment groups could be detected. We found no significant differences in quality-adjusted life-years between the groups. CONCLUSIONS:Cost-utility did not differ significantly between the three treatment groups.
RCT Entities:
BACKGROUND: The cost-utility of brief therapy compared with cognitive-behavioural therapy (CBT) and care as usual in the treatment of depression and anxiety has not yet been determined. AIMS: To assess the cost-utility of brief therapy compared with CBT and care as usual. METHOD: A pragmatic randomised controlled trial involving 702 patients was conducted at 7 Dutch mental healthcare centres (MHCs). Patients were interviewed at baseline and then every 3 months over a period of 1.5 years, during which time data were collected on direct costs, indirect costs and quality of life. RESULTS: The mean direct costs of treatment at the MHCs were significantly lower for brief therapy than for CBT and care as usual. However, after factoring in other healthcare costs and indirect costs, no significant differences between the treatment groups could be detected. We found no significant differences in quality-adjusted life-years between the groups. CONCLUSIONS: Cost-utility did not differ significantly between the three treatment groups.
Authors: Anna D T Muntingh; Christina M van der Feltz-Cornelis; Harm W J van Marwijk; Philip Spinhoven; Willem J J Assendelft; Margot W M de Waal; Leona Hakkaart-van Roijen; Herman J Adèr; Anton J L M van Balkom Journal: BMC Health Serv Res Date: 2009-09-08 Impact factor: 2.655
Authors: Kirsten M van Steenbergen-Weijenburg; Christina M van der Feltz-Cornelis; Eva K Horn; Harm W J van Marwijk; Aartjan T F Beekman; Frans F H Rutten; Leona Hakkaart-van Roijen Journal: BMC Health Serv Res Date: 2010-01-19 Impact factor: 2.655
Authors: Clazien Bouwmans; Kim De Jong; Reinier Timman; Moniek Zijlstra-Vlasveld; Christina Van der Feltz-Cornelis; Siok Tan Swan; Leona Hakkaart-van Roijen Journal: BMC Health Serv Res Date: 2013-06-15 Impact factor: 2.655
Authors: Eric W de Heer; Jack Dekker; Jonna F van Eck van der Sluijs; Aartjan Tf Beekman; Harm Wj van Marwijk; Tjalling J Holwerda; Pierre M Bet; Joost Roth; Leona Hakkaart-Van Roijen; Lianne Ringoir; Fiona Kat; Christina M van der Feltz-Cornelis Journal: BMC Psychiatry Date: 2013-05-24 Impact factor: 3.630
Authors: Paul A J M de Bont; David P G van den Berg; Berber M van der Vleugel; Carlijn de Roos; Cornelis L Mulder; Eni S Becker; Ad de Jongh; Mark van der Gaag; Agnes van Minnen Journal: Trials Date: 2013-05-23 Impact factor: 2.279